Results 101 to 110 of about 898,102 (296)
Combined redifferentiation via HDAC inhibitor and MAPK inhibitor in thyroid cancer cells
Background and purpose: Redifferentiation therapy with MAPK inhibitor is a novel strategy for radioiodine-refractory differentiated thyroid cancer, but its efficacy is relatively low.
程凌霄, 靳雨辰
doaj
What Makes an “Ideal” Cell Line for Recombinant Adeno‐Associated Virus Production?
Several host cell types have been used to produce rAAVs to date. Cell line‐specific traits that are beneficial in the context of rAAV manufacturing are reviewed here, with the goal of developing a consensus on the ‘ideal’ characteristics that an rAAV production host should possess (created with Biorender.com).
James Conheady +6 more
wiley +1 more source
Background Glioblastoma (GBM) is the most common and most malignant primary brain cancer in adults. Despite multimodality treatment, the prognosis is still poor.
Wei Meng +8 more
doaj +1 more source
DβHB and LβHB do not inhibit HDAC activities.
Hela nuclear extract was used as a source of class I and II HDAC activity (Panel A) where as recombinant human Sir1 was used as a source of class III HDAC activity (Panel B). HDAC activities were assessed in the absence (control, “C”) or presence of 4 mM
Serge Przedborski (37633) +6 more
core +1 more source
Efficacious proteasome/HDAC inhibitor combination therapy for primary effusion lymphoma [PDF]
Primary effusion lymphoma (PEL) is a rare form of aggressive B cell lymphoma caused by Kaposi's sarcoma-associated herpesvirus (KSHV). Current chemotherapy approaches result in dismal outcomes, and there is an urgent need for new PEL therapies ...
Ramos, Juan Carlos +13 more
core +1 more source
Harnessing ferroptosis from multilayer defense networks to nanoplatforms for specific cancer therapy
Nanomaterials target metabolically‐regulated ferroptosis for cancer therapy. Iron‐based or alternative nanoplatforms integrate ferroptosis with chemotherapy, immunotherapy, or radiotherapy. They enable stimulus‐responsive therapies (photothermal, photodynamic, sonodynamic) activated by near‐infrared, light, or ultrasound, achieving potent synergistic ...
Xinyue Xu +5 more
wiley +1 more source
Engineered bacteria serve as smart, living therapeutics that target tumors, deliver drugs, and remodel immunosuppressive microenvironments. This review highlights their potential to potentiate immunotherapy, radiotherapy, and chemotherapy, offering a promising paradigm for precise and synergistic cancer treatment. Abstract The dynamic interplay between
Haonan Shen +9 more
wiley +1 more source
KMT2A-rearranged acute lymphoblastic leukemia (ALL) is characterized by deregulation of the epigenome and shows susceptibility towards histone deacetylase (HDAC) inhibition.
Tamara C. A. I. Verbeek +7 more
doaj +1 more source
The prevention and treatment of malaria requires a multi-pronged approach, including the development of drugs that have novel modes of action. Histone deacetylases (HDACs), enzymes involved in post-translational protein modification, are potential new ...
Hesping, Eva +4 more
core +1 more source
Role of HR23B, HDAC6 and Myd88 and their interplay in response to HDAC inhibitor treatment [PDF]
Abnormal epigenetic control is a common early event in tumour progression, and aberrant acetylation in particular has been implicated in tumourigenesis.
core +1 more source

